NIDCR STTR PHASE 2
1 R42 DE028212 Deepak Saxena and Xin Li as PI
Title: A Novel remedy for periodontal bone loss
The dosing, pharmacokinetic/pharmacodynamic and toxicity of the biodegradable oral gel formulation will be determined in this NIH funded 2-year STTR phase 2 project.
NIDCR STTR PHASE 1
1 R41 DE028212-01A1 Deepak Saxena and Xin Li as PI
Title: A Novel remedy for periodontal bone loss
Periodontal diseases cause significant reduction in quality of life by functional limitation; its impact is significantly associated with age and burden to society. Moreover chronic periodontal disease is associated with other systemic disease. The treatment options are invasive, painful and not always successful which result in tooth loss. The development of a biodegradable oral strip or gel formulation that could be administered through less invasive approaches to augment or replace the conventional treatment could prove to be a major step forward in the treatment of periodontal disease.
NCI STTR PHASE 1
R41 CA250892 Deepak Saxena and Xin Li as PI
Title: Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma.
Endogenous gut microbiota has recently been appreciated as important regulators of homeostasis in the healthy individual and contributors toward disease during microbiotic imbalance. We postulate that specific pathogenic gut bacteria drive pancreatic carcinogenesis in at-risk individuals via TLR activation. Our ongoing studies have shown that there are significant difference in the gut microbiome of patients with pancreatic cancer as compared to healthy individuals. This clinical trial will be done in collaboration with Merck.